Evidence map›Paper›PMID 42484665›Full record

ArticleAnalytical and bioanalytical chemistry2026

Supporting molecular detection of A(H5N1) through development and characterization of RNA reference materials.

Eileen A Moran, Monique E Hunter, Jason G Kralj, Kristine Gierz, Julia C Frederick, Jimma Liddell, Lisa M Keong, Bo Shu, John R Barnes, Jasmine Chaitram and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Eileen A MoranBiomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, MD, USA. eileen.moran@nist.gov.ORCID http://orcid.org/0009-0005-5089-9442
Monique E HunterBiosystems and Biomaterials Division, National Institute of Standards and Technology, Gaithersburg, MD, USA.ORCID http://orcid.org/0009-0005-5490-2557
Jason G KraljBiosystems and Biomaterials Division, National Institute of Standards and Technology, Gaithersburg, MD, USA.ORCID http://orcid.org/0000-0003-4565-1176
Kristine GierzStatistical Engineering Division, National Institute of Standards and Technology, Gaithersburg, MD, USA.ORCID http://orcid.org/0000-0002-4919-4841
Julia C FrederickInfluenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Jimma LiddellInfluenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.ORCID http://orcid.org/0009-0007-0226-5183
Lisa M KeongInfluenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-8211-659X
Bo ShuInfluenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.
John R BarnesDivision of Infectious Disease Readiness and Innovation, Centers for Disease Control and Prevention, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-5874-4411
Jasmine ChaitramOffice of Readiness and Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Marie K KirbyInfluenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-0859-9604
C Todd DavisInfluenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-1429-974X
Stephanie L ServetasBiosystems and Biomaterials Division, National Institute of Standards and Technology, Gaithersburg, MD, USA.ORCID http://orcid.org/0000-0002-4924-4511
Scott JacksonBiosystems and Biomaterials Division, National Institute of Standards and Technology, Gaithersburg, MD, USA.
Peter M ValloneBiomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, MD, USA.ORCID http://orcid.org/0000-0002-8019-6204
Megan H ClevelandBiomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, MD, USA.ORCID http://orcid.org/0000-0002-5584-9314

Funding

CDC HHS IAA# 24FED2400252IPC
6 · The paper itself

Abstract

In 2024, the US Centers for Disease Control and Prevention (CDC) and National Institute of Standards and Technology (NIST) initiated an interagency collaboration to bolster preparedness in the event of a pandemic scenario due to high pathogenicity avian influenza A(H5N1) clade 2.3.4.4b viruses that had been circulating in North America since 2021. Multiple spillover events into mammalian species, including an outbreak among dairy cattle and a surge in human cases, spurred the development of RNA reference materials to assist with new diagnostics development and validation. With input from CDC on sequences, NIST generated three synthetic RNA materials of A(H5N1) hemagglutinin, neuraminidase, and matrix proteins 1 and 2 gene segments. Here, we describe the development and characterization of these reference materials utilizing droplet digital reverse transcription polymerase chain reaction. Through this collaboration, we were able to rapidly provide quantified, homogeneous, stable, and epidemiologically relevant RNA reference materials to the public to aid new assay development and validation.

Indexed as

A(H5N1)Avian influenzaBird fluInfluenza A virusReference material

Identifiers

PMID42484665

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.